Fintepla® (Fenfluramine): An Update on Mechanisms, Efficacy, and Safety in the Treatment of Epileptic Encephalopathies
Sunday, December 5, 2021
-
You may need to log in to view video on this page.
OVERVIEW:
To improve understanding of safe and effective use of Fintepla in DEE patients
To improve understanding of key secondary endpoints; and key outcomes outside of seizure management (i.e. cognition)
Exhibitor: Zogenix, Inc.,
Activity Type
Scientific Exhibit
Credit
Non-CME
Format
In person
Career Stage
Early Career (typically 0-5 years from completion of training)
Mid-Career (typically 6-15 years from completion of training)
Senior (typically >15 years from completion of training)
Audience
Behavioral Health Providers
Clinicians
Fellows/Trainees
Nurses
Scientists/Researchers
Advanced Practice Providers
Advocates
Pharmacists
Technicians
Demographic
Clinical
First-time Attendees
Research
Young Professionals